The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction　- First Pilot Study in Humans.
Hydrogen gas inhalation (HI) reduced infarct size and mitigated adverse left ventricular (LV) remodeling in a rat model of acute myocardial infarction (AMI). We designed a prospective, open-label, rater-blinded clinical pilot study in patients experiencing ST-elevated MI (STEMI).



The 20 patients with an initial diagnosis of STEMI were assigned to either an HI group (1.3% H2with 26% oxygen) or a control group (26% oxygen). There were no HI-related severe adverse events. In the full analysis set, the cardiac salvage index as evaluated using cardiac magnetic resonance imaging at 7 days after primary percutaneous coronary intervention (PCI), showed no significant between-group difference (HI: 50.0±24.3%; control: 60.1±20.1%; P=0.43). However, the improvement from day 7 in the HI group was numerically greater than that in the control group in some of the surrogate outcomes at 6-month follow-up, including the LV stroke volume index (HI: 9.2±7.1 mL/m2; control: -1.4±7.2 mL/m2; P=0.03) and the LV ejection fraction (HI: 11.0%±9.3%; control: 1.7%±8.3%; P=0.11).



The first clinical study has shown that HI during PCI is feasible and safe and may also promote LV reverse remodeling at 6 months after STEMI. The study was not powered to test efficacy and a further large-scale trial is warranted. (Clinical trials registration: UMIN00006825).
Department of Cardiology, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Yoshinori
Y
Katsumata
Clinical and Translational Research Center, Keio University Hospital.
Fumiya
F
Sano
Clinical and Translational Research Center, Keio University Hospital.
Takayuki
T
Abe
Department of Emergency and Critical Care Medicine, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Tomoyoshi
T
Tamura
Department of Cardiology, Keio University School of Medicine.
Taishi
T
Fujisawa
Department of Cardiology, Keio University School of Medicine.
Yasuyuki
Y
Shiraishi
Department of Cardiology, Keio University School of Medicine.
Shun
S
Kohsaka
Department of Cardiology, Keio University School of Medicine.
Ikuko
I
Ueda
Department of Emergency and Critical Care Medicine, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Koichiro
K
Homma
Department of Emergency and Critical Care Medicine, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Masaru
M
Suzuki
Department of Radiology, Keio University School of Medicine.
Shigeo
S
Okuda
Department of Cardiology, Keio University School of Medicine.
Yuichiro
Y
Maekawa
Department of Organ Fabrication, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Eiji
E
Kobayashi
Department of Emergency and Critical Care Medicine, Keio University School of Medicine.
Shingo
S
Hori
Department of Emergency and Critical Care Medicine, Keio University School of Medicine.
Junichi
J
Sasaki
Department of Cardiology, Keio University School of Medicine.
Keiichi
K
Fukuda
Department of Cardiology, Keio University School of Medicine.|Center for Molecular Hydrogen Medicine, Keio University School of Medicine.
Motoaki
M
Sano
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006859:Hydrogen / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D010865:Pilot Projects; D011446:Prospective Studies; D000072657:ST Elevation Myocardial Infarction / Q000503:physiopathology* / Q000628:therapy*; D020257:Ventricular Remodeling / Q000187:drug effects*
D006859:Hydrogen
Cardiac magnetic resonance imaging; Hydrogen gas; Left ventricular remodeling; Myocardial infarction